| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ZHAOKE OPHTH-B Innovative Drug Jingyouling Approved for Market Launch | 1 | AASTOCKS | ||
| Fr | ZHAOKE OPHTH-B (06622): INSIDE INFORMATION - THE COMPANY'S SELF-DEVELOPED INNOVATIVE DRUG CYCLOSPORINE OPHTHALMIC GEL RECEIVES MARKETING APPROVAL FROM ... | 2 | HKEx | ||
| 09.11. | ZHAOKE OPHTH-B (06622): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 27.10. | ZHAOKE OPHTH-B Guangzhou Nansha Production Base Obtains Australian GMP Certification | 1 | AASTOCKS | ||
| 27.10. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ZHAOKE OPHTHALMOLOGY'S MANUFACTURING FACILITY OBTAINS GMP CERTIFICATION FROM THE THERAPEUTIC GOODS ADMINISTRATION ... | 1 | HKEx | ||
| 22.10. | ZHAOKE OPHTH-B (06622): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 20.10. | ZHAOKE OPHTH-B (06622): (REVISED) NEXT DAY DISCLOSURE RETURN (AMENDMENT FOR THE RETURN ON 16 OCTOBER NOVEMBER 2026) | 1 | HKEx | ||
| ZHAOKE OPHTHALMOLOGY Aktie jetzt für 0€ handeln | |||||
| 20.10. | ZHAOKE OPHTH-B (06622): (REVISED) NEXT DAY DISCLOSURE RETURN (AMENDMENT FOR THE RETURN ON 15 OCTOBER NOVEMBER 2026) | 1 | HKEx | ||
| 15.10. | ZHAOKE OPHTH-B (06622): NEXT DAY DISCLOSURE RETURN | 5 | HKEx | ||
| 30.09. | ZHAOKE OPHTH-B (06622): 2026 INTERIM REPORT | - | HKEx | ||
| 30.09. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 2 | HKEx | ||
| 30.09. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 04.09. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - CARBACHOL AND BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION (YUVEZZI) MET THE PRIMARY ENDPOINT IN THE PHASE ... | - | HKEx | ||
| 28.08. | ZHAOKE OPHTH-B (06622): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 17.08. | ZHAOKE OPHTH-B (06622): NOTICE OF BOARD MEETING | - | HKEx | ||
| 12.08. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING AN EXCLUSIVE DISTRIBUTION AND PROMOTION AGREEMENT WITH PHARMENTUM BIOPHARMA TO COMMERCIALIZE ... | 1 | HKEx | ||
| 20.07. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - INNOVATIVE PRESBYOPIA DRUG YUVEZZI APPROVED BY THE PHARMACEUTICAL ADMINISTRATION BUREAU OF THE GOVERNMENT ... | 1 | HKEx | ||
| 13.07. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERED INTO A DEFINITIVE AGREEMENT FOR THE ACQUISITION OF THE GLOBAL RIGHTS TO NVK002 (ATROPINE SULFATE ... | - | HKEx | ||
| 09.07. | ZHAOKE OPHTH-B (06622): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 07.07. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - INNOVATIVE PRESBYOPIA DRUG YUVEZZI APPROVED FOR USE AT BOAO SUPER HOSPITAL AS A CLINICALLY URGENT IMPORTED ... | 1 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |